✦ LIBER ✦

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of the GPR40 Agonist TAK-875: Results From a Double-Blind, Placebo-Controlled Single Oral Dose Rising Study in Healthy Volunteers

✍ Scribed by Naik, Himanshu; Vakilynejad, Majid; Wu, Jingtao; Viswanathan, Prabhakar; Dote, Nobuhito; Higuchi, Tomoaki; Leifke, Eckhard

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

737 A PHASE-I, RANDOMIZED, DOUBLE-BLIND,

✍ U. Lopatin; G. Wolfgang; R. Kimberlin; D. Turnas; M. Cornprost; G. Chittick; C. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 46 KB

(210) Results from a phase I, double-bli

✍ D. Sahner; H. van Paaschen; A. Marcantonio; M. Eldon 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 43 KB

162 A RANDOMIZED DOUBLE-BLIND, PLACEBO-C

✍ P. Jochelson; J.L. van de Wetering; J. Bornstein; M. Resler; K. Anderson 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 39 KB

A phase 1, randomized, double-blind, pla

✍ Cotreau, Monette M.; Stonis, Lucille; Schwertschlag, Ullrich S. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 170 KB

First-in-Human Study of REGN668/SAR23189

✍ Radin, Allen; Ren, Haobo; Papino-Wood, Pamela; Chaudhry, Usman; Hamilton, Jennif 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Safety, pharmacokinetics, and pharmacody

✍ Gupta, Abhya; Yong, Chan-Loi; Madwed, Jeffrey B; Staehle, Hildegard; Wood, Chest 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 151 KB